ClinicalTrials.gg
RecruitingNCT07625553CSA-AKIUpdated Jun 4, 2026

Study of the Relaxin Agonist R2R01 in Patients at High Risk for Cardiac Surgery Associated- Acute Kidney Injury

A Phase 2 interventional study of R2R01 and Placebo in Acute Kidney Injury, sponsored by River 2 Renal Corp.. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by River 2 Renal Corp. · Phase 2, Interventional, and Prevention

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
430
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies in Acute Kidney Injury with a site in Italy — 16 open to participants now, 19 under way, none of them phase 3. Acute Kidney Injury · Italy.

Planned enrollment
12th of 36
430 · median 254
Started
2026
with 3 others
Phase 2
4 of 73
2 open now
Primary completion
2027-04
later than 14 of 18 live
Registered
71st of 73
by date

Among the 73 studies in Acute Kidney Injury with a site in Italy, this one is the 12th largest by planned enrollment of the 36 interventional ones that give a count, is one of 4 that started in 2026, is one of 4 in phase 2, reaches primary completion later than 14 of the 18 other live ones, and was the 71st registered.

Acute Kidney Injury

1,691 studies on the registry are indexed under Acute Kidney Injury; 393 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

16 of the 73 studies in Acute Kidney Injury with a site in Italy are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 230 Acute Kidney Injury studies recruiting now, 162 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Acute Kidney Injury with a site in Italy, or all of them as a file.
02

Study summary

This is a Phase 2, dose-ranging, double-blind, double-dummy, placebo-controlled, randomized study preceded by an open label safety run-in, in patients at high risk for Cardiac Surgery Associated - Acute Kidney Injury (CSA-AKI) following coronary artery bypass graft (CABG), valve surgery, aortic surgery, or a combination of the above, involving cardiopulmonary bypass (CPB).

Subjects are eligible for screening if they are scheduled for non-emergent CABG, valve surgery, surgery of the ascending part of the aorta, or a combination of the above, involving CPB, within 4 weeks after screening. In addition, subjects are eligible if AKI risk factors are present (at screening): a. If isolated surgery (CABG, single valve surgery, or of the ascending part of the aorta surgery) is scheduled, at least two AKI risk factors should be present b. If combined surgery is scheduled, at least one AKI risk factor should be present Risk factors for AKI are defined below: • Chronic kidney disease (CKD) stage III • Diabetes mellitus on pharmacological treatment • Confirmed diagnosis of hypertension • Documented history of Chronic Heart Failure with New York Heart Association (NYHA) class III or higher

  • Left ventricular ejection fraction (LVEF) ≤40%
  • Peripheral vascular disease defined as one or more of the following:

claudication, carotid occlusion or >50% stenosis, amputation for arterial disease, previous or planned intervention on the abdominal aorta, limb arteries or carotids.

  • Stroke/transient ischemic attack (TIA) defined as sudden onset of focal or global brain, spinal cord, or retinal vascular damage, resulting in symptoms and signs of acute nervous system defects, which is associated with cerebral circulation disorders
  • Documented atrial fibrillation (AF) on the ECG performed at the screening visit
  • Anemia with hemoglobin ≤11 g/dL at any time during the 3-month period before or at the time of screening
  • Body Mass Index (BMI) ≥ 30 kg/m2
  • Age ≥70 years at the time of screening The first dose of Investigational Medicinal Product (IMP: R2R01 or Placebo) will be administered subcutaneously (SC) the day before surgery at 06:00 PM (+/- 30 min); the second dose will be administered SC on the day of surgery between 07:00 and 08:00 AM when the surgery is scheduled for the morning, or between 11:00 AM and 12:00 PM when the surgery is scheduled for the afternoon; subsequent doses will be administered SC every 24 hours (+/- 90 min.) starting 24 hours after the second dose, and will continue to be administered until postoperative Day 5 or discharge, whichever occurs first. The follow-up period extends until postoperative Day 30.

The study consists of:

A. An Open-Label Safety Run-In Part, followed by B. A Double-Blind, Placebo-Controlled, Randomized Part A. An Open-Label Safety Run-In Part The first 10 subjects will be treated with R2R01 5.0 mg SC to ascertain its safety in this population. The Safety Run-In part will be run at the San Raffaele Hospital in Milan (PI Dr. Landoni). Data collected will include but will not be limited to:

(1) detailed hemodynamic parameters; (2) use of vasopressors and/or inotropic agents during surgery and in the postoperative period; (3) incidence, severity, and relationship of adverse events (AEs), including serious adverse events (SAEs); (4) postoperative clinical course; (5) available PK data.

A Scientific Review Committee (SRC), consisting of three CSA-AKI experts and at least one medical representative of the Sponsor, will review the data from the 5.0 mg dose cohort (open-label Part), based on the safety and available pharmacokinetic data collected from the 10 enrolled patients through postoperative Day 7 or discharge, whichever occurs first. If the SRC agrees to proceed with the 5.0 mg dose, enrollment will open to the randomized part B of the study. If instead, the SRC determines that the 5.0 mg dose is not appropriate, a new dose (i.e., 2.5 mg) will be selected by the SRC for evaluation in 10 additional subjects enrolledin the open-label safety run-in part. Upon completion of the Open-Label Safety Run-In Part, and once the SRC has determined the appropriate R2R01 dose(s) to be tested, enrollment will open to the Double-Blind, Placebo-Controlled, Randomized Part. B. Double-Blind, Placebo-Controlled, Randomized Part Approximately 430 patients will be randomly assigned in a 1:1:1 manner to receive one of the two doses of R2R01or placebo. At randomization, patients will be stratified by presence of CKD stage III (strata: eGFR 59-30 ml/min/1.73m2 vs. eGFR ≥60 ml/min/1.73m2). The randomized part will be conducted at all investigational sites.

AKI will be staged according to KDIGO as follows: Stage 1: increase in SCr ≥0.3 mg/dL or an increase in serum creatinine ≥1.5-fold to 2-fold from baseline.

Stage 2: incrincrease in SCr >2-fold to 3-fold from baseline. Stage 3: increase in SCr >3-fold or SCr ≥4.0 mg/dl or initiation of renal replacement therapy (RRT)

03

Conditions studied

  • Acute Kidney Injury

Browse trials for

Keywords

  • Cardiac Surgery Associated
  • Acute Kidney Injury
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is able to communicate well with the Investigator, understands and is willing to comply with all requirements of the study, and understands and signs the written form (ICF).
  • At least 18 years of age.
  • Subject is scheduled for non-emergent CABG (single or multiple vessels), valve surgery (single or multiple valves), surgery of the ascending part of the aorta, or a combination of the above, involving cardiopulmonary bypass (CPB), AND risk factors for acute kidney injury (AKI) are present (at screening) as specified below:

    1. If only one type of surgery is scheduled at least two AKI risk factors should be present
    2. If any combined surgery is scheduled at least one AKI risk factor should be present
  • Have stable renal function per Investigator assessment.
  • Subject agrees not to participate in another interventional study after signing the ICF and until the end of study (EoS) visit has been completed.
  • Both female patients, as well as female partners of male patients who are of must be willing to not become pregnant for the complete duration of the study until 90 days after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Patient currently enrolled into another interventional clinical trial.
  • Subject is scheduled for emergent surgery.
  • Cardiac surgery planned to be performed "off-pump" without CPB.
  • Expected CPB duration \<60 minutes.
  • Body weight \<50 kg; >120 kg.
  • Presence of AKI (KDIGO criteria) at the time of randomization.
  • Current, prior, or scheduled renal replacement therapy.
  • Patients who are post-nephrectomy.
  • Patients with CKD of equal or more than stage IV (≤30 ml/min/1.73 m2).
  • Patient with a kidney transplant.
  • Subject has a known or suspected glomerulonephritis at the time of randomization.
  • Cardiogenic shock, hemodynamic instability, mechanical ventilation, intra-aortic balloon pump (IABP), left ventricular assist device (LVAD) or other forms of mechanical circulatory support (MCS), within 7 days prior to surgery.
  • Patient received inotropes or vasopressors within 48 hours prior to the day of surgery.
  • Known or suspected sepsis.
  • Confirmed or suspected endocarditis
  • Other current active infection requiring antibiotic treatment.
  • Patient has severe liver disease ( score >7 points).
  • Recently received (within the last 4 weeks) or is anticipated to receive before the end of the study chemotherapy which can interfere with kidney function (e.g. Platinum agents).
  • Preoperative frailty (impaired mobility defined as patients requiring a wheelchair; and severe malnutrition defined as \<16 kg/m²).
  • Patient previously enrolled and randomized into this study.
  • Pregnant or nursing (lactating) women, where pregnancy was defined as the state of a female after conception and until the termination of gestate, confirmed by a positive human chorionic gonadotropin laboratory.
  • Known to the study drug or any of its .
  • Any medical or social condition deemed by the investigator to be likely to interfere with a patient's ability to give , cooperate, and participate in the study or to be likely to interfere with the interpretation of the results.
  • Patient who is in a relationship of dependency with the sponsor, investigator or trial site, or committed to an institution by virtue of an order issued by judicial or administrative authorities.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
430 participants (estimated)

Study arms

  • Experimental
    R2R01 at a dose of 5.0 mg

    Drug

    Drug: R2R01

  • Experimental
    R2R01 at a dose of 2.5 mg

    Drug

    Drug: R2R01

  • Placebo comparator
    Placebo

    Placebo

    Other: Placebo

Interventions

  • DrugR2R01

    R2R01 (i.e., 5.0 mg and 2.5 mg, or alternative doses, as recommended by the SRC)

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. The safety and efficacy of R2R01 for prevention of AKI (Proportion of subjects deve) after cardiac surgery (CABG, valve surgery, aortic surgery, or a combination of the above) involving CPB, in subjects with additional risk factors for developing CSA-AKI

    The outcome will be measured as: • Nature, of treatment-emergent adverse events (TEAEs).

    Time frame: 18 months

  2. The safety and efficacy of R2R01 for prevention of AKI (Proportion of subjects deve) after cardiac surgery (CABG, valve surgery, aortic surgery, or a combination of the above) involving CPB, in subjects with additional risk factors for developing CSA-

    The outcome will be measured as frequency of treatment-emergent adverse events (TEAEs).

    Time frame: 18 months

  3. The safety and efficacy of R2R01 for prevention of AKI (Proportion of subjects deve) after cardiac surgery (CABG, valve surgery, aortic surgery, or a combination of the above) involving CPB, in subjects with additional risk factors for developing CSA-AKI

    The outcome will be measured as severity of treatment-.emergent adverse events (TEAEs).

    Time frame: 18 months

Secondary outcomes

  1. Evaluation of R2R01 for the reduction of postoperative AKI severity

    \- Severity grade of AKI within 7 days after start of cardiac surgery based on SCr (serum creatinine)

    Time frame: 18 months

  2. - Evaluation R2R01 for the reduction of postoperative AKI duration

    Duration of AKI defined as the number of days meeting the definition of AKI

    Time frame: 18 months

  3. The efficacy of R2R01 on renal function

    \- Change in SCr (serum creatinine) (and corresponding eGFR values) at postoperative hours 12, 24, 48, 72, and postoperative Days 7 and 30, versus baseline

    Time frame: 18 months

  4. - Evaluation R2R01 for the reduction of major adverse kidney events (MAKE) defined as all-cause mortality, RRT and/or ≥25% sustained reduction of kidney function compared to baseline, at postoperative Day 7, and at postoperative Day 30.

    \- Proportion of subjects with a major adverse kidney event (MAKE) defined as all-cause mortality, RRT and/or ≥ 25% sustained reduction of kidney function (i.e., a reduction of eGFR of 25% or more compared to the baseline presurgery sample, using the Chronic Kidney DiseaseEpidemiology Collaboration (CKD-EPI) equations (with either SCr, CyC, or both) at postoperative Day 7 and at postoperative Day 30

    Time frame: 18 months

  5. - Evaluation the effect of R2R01 on the length of postoperative stay in Intensive Care Unit (ICU) and overall hospitalization time.

    \- Length of ICU stay (in hours) defined as the duration of stay in the ICU immediately following surgery (or recovery room post-surgery) until ICU discharge

    Time frame: 18 months

  6. Evaluation of the effect of R2R01 for the reduction of hospital readmissions at postoperative Day 30

    Proportion of subjects readmitted to the hospital at postoperative Day 30.

    Time frame: 13 months

  7. The evaluation of the efficacy of R2R101 on renal function

    Change cystatin C (and corresponding eGFR values) at postoperative hours 12, 24, 48, 72, and postoperative Days 7 and 30, versus baseline

    Time frame: 18 months

  8. - Evaluation the effect of R2R01 on the length of postoperative stay in Intensive Care Unit (ICU) and overall hospitalization time.

    \- Lenght of Hospital stay (in days) defined as duration of stay in the hospital from the day of surgery to hospital disharge.

    Time frame: 18 months

  9. - Evaluation the effect of R2R01 on the length of postoperative stay in Intensive Care Unit (ICU) and overall hospitalization time.

    \- ICU free daysn and hospital free days.

    Time frame: 18 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2027, 11 months after the start.

Of 57 phase 2 interventional studies under Acute Kidney Injury, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 42. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2026
First posted
Jun 4, 2026
StartActual
Apr 7, 2026
Primary completionEst.
Apr 1, 2027
CompletionEst.
Apr 30, 2027
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07625553
Lead sponsor
River 2 Renal Corp.
Responsible party
Sponsor
First posted
Jun 4, 2026
Start date
Apr 7, 2026
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Jun 4, 2026

Study contacts

Minh Nguyêt Duong, MD
Contact
mnduong@narrowrivermgmt.com
+316 28 44 33 89

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion